The ALTITUDE-AD Study
Help us learn more about an investigational drug for early Alzheimer’s disease.
Memory and thinking problems may be a sign of early Alzheimer’s disease. Changes in the brain related to Alzheimer’s disease begin years before there are any signs or symptoms of the disease.1 Alzheimer’s disease tends to develop slowly and gradually worsens over time.
The ALTITUDE-AD Study is exploring whether an investigational drug could be safe and effective in treating Alzheimer’s disease.
Take a short prescreening survey to see if you may qualify.
Study participants must
Be between the ages of 50 and 90 years old
Be experiencing memory loss or have a current diagnosis* of
Have a study partner (such as a spouse, family member, or friend) who can accompany them to study visits
*A current diagnosis is not required for study participation. However, the study will include tests to help determine if your memory problems may be due to mild cognitive impairment or mild Alzheimer’s disease.
For a complete list of criteria and more information about participating in the ALTITUDE-AD Study, please contact a study site.
References